PD-(L)1/VEGF这个靶点,注定将在中国创新药的发展历史上,留下无法磨灭的印记。在这一组合靶点的开发上,中国的速度领先发达国家数年且发挥着主导作用,引爆了全球行情。新年伊始,这个被业界寄予 “下一代肿瘤免疫基石药物” 厚望的赛道,迎来了新“玩家”。1月12日,艾伯维通过授权引进的方式获得了荣昌生物RC148除大中华区以外地区的独家开发、生产和商业化权益,荣昌生物将收到6.5亿美元首付款,最高...
Source LinkPD-(L)1/VEGF这个靶点,注定将在中国创新药的发展历史上,留下无法磨灭的印记。在这一组合靶点的开发上,中国的速度领先发达国家数年且发挥着主导作用,引爆了全球行情。新年伊始,这个被业界寄予 “下一代肿瘤免疫基石药物” 厚望的赛道,迎来了新“玩家”。1月12日,艾伯维通过授权引进的方式获得了荣昌生物RC148除大中华区以外地区的独家开发、生产和商业化权益,荣昌生物将收到6.5亿美元首付款,最高...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.